

Supplementary Table 7. Number of events in the primary outcome, its components, and death from any cause for ARB vs ACEi using a propensity-score—matched analysis of patients in CPRD (sensitivity analysis)				
Outcome	CPRD: Propensity-score—matched			ONTARGET
	ACEi (N=15,462)	ARB (N=15,462)	ARB vs ACEi	Telmisartan vs Ramipril
	<i>Number (percent)</i>		<i>Hazard ratio (95% CI)</i>	
Primary composite: Death from cardiovascular causes, myocardial infarction, stroke, or hospitalisation for heart failure	2539 (16.4)	2453 (15.9)	0.97 (0.92, 1.02)	1.01 (0.94, 1.09)
Main secondary outcome: Death from cardiovascular causes, myocardial infarction or stroke	2234 (14.5)	2173 (14.1)	0.98 (0.92, 1.04)	0.99 (0.91, 1.07)
Myocardial infarction	1806 (11.7)	1721 (11.1)	0.96 (0.90, 1.03)	1.07 (0.94, 1.22)
Stroke	535 (3.5)	591 (3.8)	1.10 (0.98, 1.24)	0.91 (0.79, 1.05)
Hospitalisation for heart failure	542 (3.5)	513 (3.3)	0.94 (0.83, 1.06)	1.12 (0.97, 1.29)
Death from cardiovascular causes	655 (4.2)	649 (4.2)	0.98 (0.88, 1.09)	1.00 (0.89, 1.12)
Death from non-cardiovascular causes	852 (5.5)	856 (5.5)	0.99 (0.90, 1.09)	0.96 (0.83, 1.10)
Death from any cause	1507 (9.8)	1505 (9.7)	0.99 (0.92, 1.06)	0.98 (0.90, 1.07)
Notes: Propensity-score—matched cohort developed using trial-matched ACEi patients 1:1 matched to closest trial-eligible ARB period. Myocardial infarction and stroke include both fatal and non-fatal events. ONTARGET results are from published findings.				